Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18559514 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kawamura H, et al. (2008) Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 68, 4683-92 18559514
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y949-p - VEGFR2 (mouse)
Orthologous residues
VEGFR2 (human): Y951‑p, VEGFR2 (mouse): Y949‑p, VEGFR2 (rat): Y947‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE VEGFR2 (mouse)

Y1052-p - VEGFR2 (mouse)
Orthologous residues
VEGFR2 (human): Y1054‑p, VEGFR2 (mouse): Y1052‑p, VEGFR2 (rat): Y1050‑p
Characterization
 Methods used to characterize site in vivo peptide sequencing, western blotting
 Relevant cell lines - cell types - tissues:  endothelial-aorta, PAE (endothelial)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse, pig
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE VEGFR2 (mouse)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase

Y1057-p - VEGFR2 (mouse)
Orthologous residues
VEGFR2 (human): Y1059‑p, VEGFR2 (mouse): Y1057‑p, VEGFR2 (rat): Y1055‑p
Characterization
 Methods used to characterize site in vivo peptide sequencing, western blotting
 Relevant cell lines - cell types - tissues:  endothelial-aorta, PAE (endothelial)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse, pig
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase

Y1173-p - VEGFR2 (mouse)
Orthologous residues
VEGFR2 (human): Y1175‑p, VEGFR2 (mouse): Y1173‑p, VEGFR2 (rat): Y1171‑p
Characterization
 Methods used to characterize site in vivo peptide sequencing, western blotting
 Relevant cell lines - cell types - tissues:  endothelial-aorta, PAE (endothelial)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse, pig
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase

Y1212-p - VEGFR2 (mouse)
Orthologous residues
VEGFR2 (human): Y1214‑p, VEGFR2 (mouse): Y1212‑p, VEGFR2 (rat): Y1210‑p
Characterization
 Methods used to characterize site in vivo peptide sequencing, western blotting
 Relevant cell lines - cell types - tissues:  endothelial-aorta, PAE (endothelial)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse, pig
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE VEGFR2 (mouse)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.